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Abstract
Background
The factors influencing three major outcomes–death, stroke/systemic embolism (SE), and
major bleeding–have not been investigated in a large international cohort of unselected
patients with newly diagnosed atrial fibrillation (AF).
Methods and results
In 28,628 patients prospectively enrolled in the GARFIELD-AF registry with 2-year follow-
up, we aimed at analysing: (1) the variables influencing outcomes; (2) the extent of imple-
mentation of guideline-recommended therapies in comorbidities that strongly affect out-
comes. Median (IQR) age was 71.0 (63.0 to 78.0) years, 44.4% of patients were female,
median (IQR) CHA2DS2-VASc score was 3.0 (2.0 to 4.0); 63.3% of patients were on antico-
agulants (ACs) with or without antiplatelet (AP) therapy, 24.5% AP monotherapy, and
12.2% no antithrombotic therapy. At 2 years, rates (95% CI) of death, stroke/SE, and major
bleeding were 3.84 (3.68; 4.02), 1.27 (1.18; 1.38), and 0.71 (0.64; 0.79) per 100 person-
years. Age, history of stroke/SE, vascular disease (VascD), and chronic kidney disease
(CKD) were associated with the risks of all three outcomes. Congestive heart failure (CHF)
was associated with the risks of death and stroke/SE. Smoking, non-paroxysmal forms of
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AF, and history of bleeding were associated with the risk of death, female sex and heavy
drinking with the risk of stroke/SE. Asian race was associated with lower risks of death and
major bleeding versus other races. AC treatment was associated with 30% and 28% lower
risks of death and stroke/SE, respectively, compared with no AC treatment. Rates of pre-
scription of guideline-recommended drugs were suboptimal in patients with CHF, VascD, or
CKD.
Conclusions
Our data show that several variables are associated with the risk of one or more outcomes,
in terms of death, stroke/SE, and major bleeding. Comprehensive management of AF
should encompass, besides anticoagulation, improved implementation of guideline-recom-
mended therapies for comorbidities strongly associated with outcomes, namely CHF,
VascD, and CKD.
Trial registration
ClinicalTrials.gov NCT01090362
Introduction
Atrial fibrillation (AF), the most frequent of all sustained cardiac arrhythmias, is associated
with increased risk of death, stroke/systemic embolism (SE), and bleeding. Currently recom-
mended management approaches include rhythm and/or rate control, and anticoagulation for
the prevention of stroke/SE in at-risk patients without contraindication [1, 2]. We previously
showed in the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIEL-
D-AF) registry that at 2-year follow-up, death was the most frequent major adverse event,
occurring at a much higher rate than stroke/SE or major bleeding [3]. Stroke-related death
accounted for less than 10% of all causes of death.
In this report, we analyse at 2-year follow-up the outcomes of 28,628 patients with newly
diagnosed AF recruited in the first three cohorts of GARFIELD-AF, with two objectives. The
primary objective was to identify the variables associated with the risks of all three major out-
come measures, namely death, stroke/SE and bleeding, particularly those linked to modifiable
risk factors. The secondary objective was to assess compliance with guidelines as regards drug
prescription in comorbidities identified to strongly affect outcomes, namely congestive heart
failure (CHF), vascular disease (VascD), and chronic kidney disease (CKD) [4–6].
Methods
The design of the GARFIELD-AF registry was reported previously [7, 8]. Briefly, men and
women aged18 years with non-valvular AF diagnosed according to standard local proce-
dures within the previous 6 weeks, and with at least one non-prespecified risk factor for stroke
as judged by the investigator, were eligible for inclusion [8].
Patients were enrolled prospectively and consecutively. Investigator sites were selected
randomly (apart from 18 sites) and represent the different care settings in each participating
country (office-based practice; hospital departments including neurology, cardiology, geriat-
rics, internal medicine and emergency; anticoagulation clinics; and general or family practice)
[7, 8].
Risk factors for outcomes in atrial fibrillation
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Procedures and outcome measures
Baseline characteristics collected at inclusion in the registry included medical history, care set-
ting, type of AF, date and method of diagnosis, symptoms, antithrombotic treatment (vitamin
K antagonists [VKAs], non-vitamin K antagonist oral anticoagulants [NOACs], and antiplate-
let [AP] treatment), as well as all cardiovascular drugs. Race was classified by the investigator
in agreement with the patient [8]. Data on components of the CHA2DS2-VASc and HAS-
BLED risk stratification schemes were collected to assess the risks of stroke and bleeding retro-
spectively. HAS-BLED scores were calculated excluding fluctuations in international normal-
ised ratio.
Collection of follow-up data occurred at 4-monthly intervals up to 24 months [7, 8]. Stan-
dardised definitions for clinical events have been reported previously [7, 8]. In brief, baseline
characteristics and treatments, and the incidence of death (cardiovascular and non-cardiovas-
cular), stroke/SE, and bleeding were recorded. Submitted data were examined for complete-
ness and accuracy by the coordinating centre (Thrombosis Research Institute, London, UK),
and data queries were sent to study sites. GARFIELD-AF data are captured using an electronic
case report form (eCRF). In accordance with the study protocol, 20% of all eCRFs are moni-
tored against source documentation [9].
Data for the analysis in this report were extracted from the study database on 28 July 2016.
Definitions
VascD included peripheral artery disease or coronary artery disease with a history of acute cor-
onary syndromes (ACS). CKD was classified according to National Kidney Foundation guide-
lines into two groups: moderate-to-severe (stages 3–5), or mild (stages 1 and 2) or none [6].
CHF was defined as current/prior history of CHF or left ventricular ejection fraction of<40%.
Guideline-recommended therapies included angiotensin-converting enzyme (ACE) inhibi-
tors/angiotensin receptor blockers (ARBs), betablockers, aldosterone blockade, and loop
diuretics for CHF; aspirin (ASA), statins, ACE inhibitors/ARBs, and betablockers for VascD;
and ACE inhibitors/ARBs for CKD.
Statistical analysis
Continuous variables are expressed as median (interquartile range, IQR) and categorical vari-
ables as frequency and percentage. Baseline rates of prescription of guideline-recommended
drugs in CHF, VascD, and CKD are displayed with the baseline rate of prescription of antico-
agulants (ACs).
Differences in medians were tested using the Wilcoxon rank-sum (Mann-Whitney) test.
Differences in proportions were tested using the two-sample test of proportion. Trends were
assessed using an extension of the Wilcoxon rank-sum test.
Risk factors for outcomes in atrial fibrillation
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Occurrence of major clinical outcomes is expressed as person-time event rates (per 100 per-
son-years) and 95% confidence intervals (CIs). Person-year rates were estimated using a Pois-
son model with the number of events as the dependent variable and the log of time as an
offset, i.e., a covariate with a known coefficient of 1. Only the first occurrence of events was
taken into account. Hazard ratios (HRs) and 95% CIs were estimated using a proportional haz-
ards Cox model based on five imputed datasets. The imputed datasets were created by the
Multiple Imputation by Chained Equations (MICE) algorithm [10, 11]. The proportional haz-
ard assumption was assessed visually using plots of the survivor function. The following vari-
ables were included in the Cox model: age groups (<65, 65–69, 70–74,75 years), gender,
race (Caucasian/Hispanic/Latino, Asian, other race–including Afro-Caribbean, mixed/other,
and unwilling to declare/not recorded), smoking (no, ex, current), diabetes, hypertension, pre-
vious stroke/transient ischaemic attack (TIA)/SE, history of bleeding, cardiac failure, VascD,
moderate-to-severe renal disease, AC treatment, type of AF (new onset [unclassified], paroxys-
mal, persistent, permanent), and alcohol consumption (abstinent, light, moderate, heavy).
Hazard ratios were adjusted for all variables in the model.
Data analysis was performed with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and
Stata Statistical Software: Release 14.2 (StataCorp, College Station, TX, USA). Forest plots were
created in R 3.3.1 (R Core Team, Vienna, Austria).
Results
Study population
The study population comprised 28,628 prospective patients with AF enrolled in GARFIEL-
D-AF between March 2010 and October 2014 and followed for 2 years. Patients came from
1048 study sites representative of routine practice in each of 32 countries. Two-year follow-up
was achieved in 91% of patients. At baseline, the median (IQR) age was 71.0 (63.0 to 78.0)
years and 44.4% of patients were female. The median (IQR) CHA2DS2-VASc and HAS-BLED
scores were 3.0 (2.0 to 4.0) and 1.0 (1.0 to 2.0), respectively. Other baseline characteristics are
shown in Table 1. At diagnosis of AF, 63.3% of patients were prescribed AC therapy (46.3%
VKAs and 17.0% NOACs, with or without APs), 24.5% received AP monotherapy, and 12.2%
received no AC or AP therapy.
Baseline therapies
In patients with CHF, the rates of prescription of guideline-recommended therapies were no
drug in 11.7%, one drug in 25.1%, two drugs in 33.6%, three drugs in 23.3%, and four drugs in
6.4% of patients (Table 2). These figures were not affected by the heart failure stage (New York
Heart Association I–II vs III–IV).
In patients with VascD, the rates of prescription of guideline-recommended therapies were
no drug in 6.0%, one drug in 17.0%, two drugs in 28.9%, three drugs in 31.7%, and four drugs
in 16.4% (Table 2).
Details about guideline-recommended drugs for both CHF and VascD are in Table 3.
Of the patients with CKD, 36.1% were prescribed ACE inhibitors/ARBs, drugs that may
slow the rate of kidney function deterioration.
Clinical outcomes
During 2-year follow-up, the rates (95% CI) of all-cause mortality, stroke/SE, and major bleed-
ing (first occurrences) were 3.84 (3.68; 4.02), 1.27 (1.18; 1.38), and 0.71 (0.64, 0.79) per 100 per-
son-years, respectively (Table 4). Cardiovascular death occurred at a rate of 1.46 (1.36; 1.57)
Risk factors for outcomes in atrial fibrillation
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Table 1. Baseline characteristics of all patients (N = 28,628).
Variable Value %
Female, n/n, % 12,711/28,628 44.4
Age, median (IQR), years 71.0 (63.0 to 78.0) n/a
Age group, n/n, %
<65 years 8517/28,628 29.8
65–74 years 9323/28,628 32.6
75 years 10,788/28,628 37.7
Race, n/n, %
Afro-Caribbean 53/28,628 0.2
Asian (not Chinese) 5621/28,628 19.6
Chinese 1541/28,628 5.4
Caucasian 18,199/28,628 63.6
Hispanic/Latino 2032/28,628 7.1
Mixed/other 407/28,628 1.4
Unwilling to declare/not recorded 775/28,628 2.7
Body mass index, median (IQR), kg/m2 27.0 (24.0 to 31.0) n/a
Pulse, median (IQR), bpm 84.0 (70.0 to 105.0) n/a
Systolic blood pressure, median (IQR), mm Hg 131.0 (120.0 to 145.0) n/a
Diastolic blood pressure, median (IQR), mm Hg 80.0 (70.0 to 89.0) n/a
Left ventricular ejection fraction <40%, n/n (%) 1665/16,379 10.2
Type of atrial fibrillation, n/n (%)
Permanent 3638/28,626 12.7
Persistent 4367/28,626 15.3
Paroxysmal 7681/28,626 26.8
New onset (unclassified) 12,940/28,626 45.2
Medical history, n/n (%)
Congestive heart failure 3532/17,158 20.6
Coronary artery disease 3418/17,158 19.9
Acute coronary syndromes 1613/17,155 9.4
Carotid occlusive disease 867/28,425 3.1
Pulmonary embolism/deep vein thrombosis 768/28,535 2.7
Coronary artery bypass graft 854/28,067 3.0
Stroke/transient ischaemic attack 3424/28,626 12.0
Systemic embolism 194/28,537 0.7
History of bleeding 780/28,553 2.7
History of hypertension 22,161/28,583 77.5
Hypercholesterolaemia 11,514/28,080 41.0
Diabetes mellitus 6211/28,626 21.7
Cirrhosis 154/28,350 0.5
Chronic renal disease, n/n (%)
None or mild (Grades I and II) 25,655/28,625 89.6
Moderate to severe (Grades III to V) 2970/28,625 10.4
Dementia 410/28,514 1.4
Alcohol consumption, n/n (%)
Abstinent/light 21,278/24,218 87.9
Moderate 2335/24,218 9.6
Heavy 605/24,218 2.5
Current/previous smoker, n/n (%) 9062/26,046 34.8
(Continued)
Risk factors for outcomes in atrial fibrillation
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per 100 person-years and constituted 37.9% of deaths (Tables 4 and 5). Non-cardiovascular
death occurred at a rate of 1.44 (1.34; 1.55) per 100-person-years and represented 37.4% of
deaths (Tables 4 and 5). The most frequent known causes of death were CHF (12.1% of all
deaths) and malignancy (11.1% of all deaths) (Table 5).
Of the strokes occurring during follow-up, 70.6% were primary ischaemic, 10.6% were pri-
mary intracerebral haemorrhages, and 18.9% were undetermined (Table 5). Bleeding events
were more likely to be non-major clinically relevant (57.7%) than major (42.3%), and a minor-
ity were fatal (6.9%; Table 5).
Table 1. (Continued)
Variable Value %
Antithrombotic treatment, n/n (%)
Vitamin K antagonists 9947/28,221 35.2
Vitamin K antagonists + antiplatelet 3127/28,221 11.1
Factor Xa inhibitors 2300/28,221 8.1
Factor Xa inhibitors + antiplatelet 643/28,221 2.3
Direct thrombin inhibitors 1499/28,221 5.3
Direct thrombin inhibitors + antiplatelet 356/28,221 1.3
Antiplatelet only 6905/28,221 24.5
None 3444/28,221 12.2
CHA2DS2-VASc score, median (IQR) 3.0 (2.0 to 4.0) n/a
CHA2DS2-VASc score categories, n/n (%)
0 687/27,973 2.5
1 3352/27,973 12.0
2 5539/27,973 19.8
3 6753/27,973 24.1
4 6165/27,973 22.0
5 3255/27,973 11.6
6–9 2222/27,973 7.9
HAS-BLED score, median (IQR) 1.5 (0.9) n/a
HAS-BLED score categories, n/n (%)
0 2494/19,402 12.9
1 7998/19,402 41.2
2 6483/19,402 33.4
3 2054/19,402 10.6
4 338/19,402 1.7
5 34/19,402 0.2
6–9 1/19,402 0.0
Care setting specialty at diagnosis, n/n (%)
Cardiology 18,217/28,626 63.6
Geriatrics 117/28,626 0.4
Internal medicine 5287/28,626 18.5
Neurology 568/28,626 2.0
Primary care/general practice 4437/28,626 15.5
CHA2DS2-VASc, cardiac failure, hypertension, age75 (doubled), diabetes, stroke (doubled)-vascular disease, age
65–74, and sex category (female); IQR, interquartile range.
‘modified’ HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or
predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each).
https://doi.org/10.1371/journal.pone.0191592.t001
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The rates (95% CI) of myocardial infarction/ACS and of new onset or worsening of CHF
during follow-up were 0.68 (0.61; 0.75) and 1.96 (1.84; 2.08) per 100 person-years, respectively
(Table 4).
Factors influencing outcomes
After adjustment, the following baseline variables were found to be significantly associated
with a higher risk of death: age, ‘other race’ (vs Caucasian/Hispanic/Latino), smoking, diabetes
mellitus, history of stroke/TIA/SE, history of bleeding, cardiac failure, VascD, moderate-to-
severe renal disease, and non-paroxysmal forms of AF (Fig 1A). The variables associated with
a higher risk of stroke/SE were: age, female sex, ‘other race’ (vs Caucasian/Hispanic/Latino),
history of stroke/TIA/SE, CHF, VascD, moderate-to-severe renal disease, and heavy alcohol
consumption (Fig 1B). Age, VascD, moderate-to-severe renal disease, and AC treatment were
independently associated with a higher risk of major bleeding (Fig 1C). In addition, we
observed a trend of increased risk of major bleeding with increasing alcohol consumption
(p<0.0001), and a substantial but not statistically significant increase in bleeding risk with pre-
vious or current smoking.
Asians had significantly lower risks of death and major bleeding compared with Caucasian/
Hispanic/Latino patients, but they also had a lower rate of comorbidities, particularly CKD
(7.5% vs 11.09%, p<0.0001), and a significantly lower age (median [IQR] 69 [60–70] vs 72
[64–79]; p<0.0001). AC treatment was associated with lower risks of death and stroke/SE and
a higher risk of major bleeding. History of hypertension and pattern of AF were not associated
with a higher risk of stroke/SE.
The rates of death, stroke/SE, and major bleeding increased progressively with increasing
grades of the CHA2DS2-VASc scoring scheme (Table 6).
Discussion
Many reports have identified the variables associated with outcomes in AF, both in terms of
stroke/SE and bleeding, but less frequently death and its causes [12–16]. This study is novel in
addressing the variables that influence the risks of all three major outcome measures in a large,
global, prospective registry of newly diagnosed AF. It confirms prior observations from a
report based on a smaller cohort of the GARFIELD-AF registry with similar baseline charac-
teristics and follow-up. We found that death was the most frequent adverse event, occurring at
threefold the rate of stroke/SE and fivefold the rate of major bleeding [3]. Cardiovascular and
Table 2. Baseline prescription of guideline-recommended therapies in patients with congestive heart failure or
vascular disease.
Number of guideline-recommended drugs, n
(%)
Patients with congestive heart
failure
Patients with vascular
disease
0 781 (11.7) 248 (6.0)
1 1675 (25.1) 708 (17.0)
2 2243 (33.6) 1205 (28.9)
3 1556 (23.3) 1320 (31.7)
4 424 (6.4) 685 (16.4)
Total 6679 (100) 4166 (100)
Guideline-recommended therapies for congestive heart failure: angiotensin-converting enzyme (ACE) inhibitors/
angiotensin receptor blockers (ARBs), betablockers, aldosterone blockade, and loop diuretics; guideline-
recommended therapies for vascular disease: aspirin, statins, ACE inhibitors/ARBs, and betablockers.
https://doi.org/10.1371/journal.pone.0191592.t002
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non-cardiovascular causes of death occurred at a similar rate. Stroke accounted for less than
5% of all deaths. The most frequent causes of death were CHF, sudden death, ACS, malig-
nancy, respiratory failure, and sepsis. Newly diagnosed AF appears to be both a marker of
unfavourable outcome linked to underlying comorbidities and a worsening factor of some
Table 3. Monotherapy and combinations of guideline-recommended therapies prescribed for patients with
congestive heart failure or vascular disease.
Guideline-recommended therapies n (%)
Congestive heart failure
1 drug
ACE inhibitor/ARB 757 (12.8)
BB 441 (7.5)
Aldosterone blockade 51 (0.9)
Loop diuretic 426 (7.2)
2 drugs
ACE inhibitor/ARB + BB 707 (12.0)
ACE inhibitor/ARB + aldosterone blockade 106 (1.8)
ACE inhibitor/ARB + loop diuretic 976 (16.5)
BB + aldosterone blockade 33 (0.6)
BB + loop diuretic 318 (5.4)
Aldosterone blockade + loop diuretic 103 (1.8)
3 drugs
ACE inhibitor/ARB + BB + aldosterone blockade 119 (2.0)
ACE inhibitor/ARB + BB + loop diuretic 1046 (17.7)
ACE inhibitor/ARB + aldosterone blockade + loop diuretic 295 (5.0)
BB + aldosterone blockade + loop diuretic 96 (1.6)
4 drugs
ACE inhibitor/ARB + BB + aldosterone blockade + loop diuretic 424 (7.2)
Vascular disease
1 drug
ASA 123 (3.0)
BB 116 (3.0)
Statin 197 (5.0)
ACE inhibitor/ARB 272 (6.9)
2 drugs
ASA + BB 91 (2.3)
ASA + statin 261 (6.7)
ASA + ACE inhibitor/ARB 175 (4.5)
BB + statin 132 (3.4)
BB + ACE inhibitor/ARB 166 (4.2)
Statin + ACE inhibitor/ARB 380 (9.7)
3 drugs
ASA + BB + statin 234 (6.0)
ASA + BB + ACE inhibitor/ARB 135 (3.4)
ASA + statin + ACE inhibitor/ARB 521 (13.3)
BB + statin + ACE inhibitor/ARB 430 (11.0)
4 drugs
ASA + BB + statin + ACE inhibitor/ARB 685 (17.5)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ASA, aspirin; BB, betablocker.
https://doi.org/10.1371/journal.pone.0191592.t003
Risk factors for outcomes in atrial fibrillation
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Table 4. Two-year event rates including additional outcomes.
Outcome N Events % Event rate
(per 100 person-years)
95% CI
All-cause death 28,628 1985 6.9 3.84 3.68; 4.02
Cardiovascular death 28,628 753 2.6 1.46 1.36; 1.57
Non-cardiovascular death 28,628 743 2.6 1.44 1.34; 1.55
Undetermined cause of death 28,628 489 1.7 0.95 0.87; 1.04
Stroke/SE 28,628 651 2.3 1.27 1.18; 1.38
Major bleed 28,628 366 1.3 0.71 0.64; 0.79
MI/ACS 28,628 348 1.2 0.68 0.61; 0.75
Congestive heart failure 28,628 988 3.5 1.96 1.84; 2.08
ACS, acute coronary syndromes; CI, confidence interval; MI, myocardial infarction; SE, systemic embolism.
https://doi.org/10.1371/journal.pone.0191592.t004
Table 5. Breakdown of primary outcomes by type of event at 2-year follow-up.
Event n (%)
All-cause death 1985
Cardiovascular causes 753 (37.9)
Congestive heart failure 240 (12.1)
Sudden/unwitnessed death 129 (6.5)
Acute coronary syndromes 82 (4.1)
Ischaemic stroke 88 (4.4)
Other 214 (10.8)
Non-cardiovascular causes 743 (37.4)
Malignancy 220 (11.1)
Respiratory failure 150 (7.6)
Infection/sepsis 147 (7.4)
Renal 49 (2.5)
Suicide 1 (0.1)
Other 176 (8.9)
Undetermined causes 489 (24.6)
Stroke (not including systemic embolism) 625
Primary ischaemic stroke 441 (70.6)
Of which secondary haemorrhagic ischaemic stroke 27 (4.3)
Primary intracerebral haemorrhage 66 (10.6)
Intracerebral 41 (6.6)
Subarachnoid 5 (0.8)
Intraventricular 7 (1.1)
Unknown 13 (2.1)
Undetermined 118 (18.9)
Bleeding events (not including minor bleeds) 866
Severity of bleed
Non-major clinically relevant 500 (57.7)
Major 366 (42.3)
Fatal 60 (6.9)
Only the first occurrence of each event was taken into account.
https://doi.org/10.1371/journal.pone.0191592.t005
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comorbidities such as CHF, ACS, and respiratory failure, which might be affected by the hae-
modynamic alterations and the embolic complications linked to AF [3, 17].
The relationships between different variables and the risks of all-cause mortality, stroke/SE,
and major bleeding are summarised in Fig 2. Four variables were associated with higher risks
of all three major outcome measures, namely older age, history of stroke/TIA, VascD, and
Fig 1. Adjusted hazard ratios for 2-year outcomes according to baseline characteristics and anticoagulant treatment: (A) all-cause mortality; (B) stroke/systemic
embolism; (C) major bleeding. ‘Anticoagulant treatment’ includes both vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. For race, ‘Asian’
includes Asian (not Chinese) and Chinese, and ‘other’ includes Afro-Caribbean, mixed/other, and unwilling to declare/not recorded. Reference groups, from top:<65
years, men, Caucasian/Hispanic/Latino, never smoker, no history of disease (for diabetes, hypertension, stroke/TIA/SE, history of bleeding, cardiac failure, vascular
disease, and renal disease), no AC treatment, paroxysmal AF, alcohol abstinence. Hazard ratios were adjusted for all variables in the model. AC, anticoagulant; AF, atrial
fibrillation; CI, confidence interval; HR, hazard ratio; SE, systemic embolism; TIA, transient ischaemic attack.
https://doi.org/10.1371/journal.pone.0191592.g001
Table 6. Crude event rates during 2-year follow-up according to CHA2DS2-VASc score.
Event CHA2DS2-VASc 0–1
(n = 4694)
CHA2DS2-VASc 2
(n = 5539)
CHA2DS2-VASc 3
(n = 6753)
CHA2DS2-VASc 4+
(n = 11,642)
Stroke/SE
n (%) 44 (0.9) 76 (1.4) 136 (2.0) 395 (3.4)
Rate per 100 person-years (95% CI) 0.52 (0.38; 0.69) 0.75 (0.60; 0.94) 1.11 (0.94; 1.32) 1.95 (1.77; 2.15)
Major bleeding
n (%) 26 (0.6) 52 (0.9) 85 (1.3) 203 (1.7)
Rate per 100 person-years (95% CI) 0.30 (0.21; 0.45) 0.51 (0.39; 0.67) 0.69 (0.56; 0.86) 1.00 (0.87; 1.14)
All-cause mortality
n (%) 123 (2.6) 208 (3.8) 391 (5.8) 1263 (10.8)
Rate per 100 person-years (95% CI) 1.44 (1.20; 1.71) 2.05 (1.79; 2.34) 3.17 (2.87; 3.50) 6.14 (5.81; 6.49)
CHA2DS2-VASc, cardiac failure, hypertension, age75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74, and sex category (female); CI, confidence
interval; SE, systemic embolism.
https://doi.org/10.1371/journal.pone.0191592.t006
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CKD. The first three variables are established predictors of stroke, and are components of the
most widely used risk assessment scheme CHA2DS2-VASc. Though CKD is not a component
of the CHA2DS2-VASc score, it has a strong influence on the risks of stroke/SE, bleeding, and
death [12, 14, 16, 18–20]. CHF, also a component of CHA2DS2-VASc, was associated with
higher risks of both death and stroke/SE. Two variables were associated with a higher risk of
death only, namely smoking and history of bleeding.
Non-paroxysmal forms of AF were also associated with a higher risk of death, but not of
stroke/SE compared with paroxysmal AF. In previous reports from randomised controlled tri-
als and registries, non-paroxysmal forms of AF were consistently reported to be associated
with a higher risk of death, but with various findings as regards the risk of stroke/SE [13, 21–
24]. Diabetes was also associated with a higher risk of death but was only marginally associated
with a higher risk of stroke/SE. Adequate blood glucose balance, shown to prevent the occur-
rence of microvascular complications and to a lesser extent cardiovascular complications, may
explain the lack of association of diabetes with the risk of stroke/SE [25, 26].
Some variables considered to be risk factors were only marginally associated with the risk
of events or had a neutral effect, for example, history of hypertension. One may assume that
history of hypertension as reported by the investigators in over 70% of the population implies
that adequate control of blood pressure was achieved in these patients. We may hypothesise
that this may have prevented remodelling of the heart chambers. Interestingly, 7.5% of patients
included in GARFIELD-AF had uncontrolled hypertension (systolic blood pressure>160
Fig 2. Relationships between variables and clinical outcomes during 2-year follow-up. Key to symbols used: upwards arrow
indicates increased risk, downwards arrow indicates reduced risk, double-headed arrow indicates no change in risk. AF, atrial
fibrillation; SE, systemic embolism; TIA, transient ischaemic attack.
https://doi.org/10.1371/journal.pone.0191592.g002
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mmHg). This subset of patients had a higher risk of stroke/SE but not of death or bleeding
compared to patients without high blood pressure (HR 1.73, 95% CI 1.37 to 2.18).
AC was associated with substantially lower risks of all-cause death (30% lower risk in AC
patients compared with non-AC patients) and stroke/SE (28% lower risk in patients receiving
AC compared with those not receiving AC), and with a 52% higher risk of bleeding compared
with no AC treatment. Reduction in mortality in association with anticoagulation may have
been due, in part, to prevention of thromboembolism in patients with CHF, sepsis, respiratory
failure, or cancer [3].
In contrast, Asian race was associated with lower risks of death and bleeding, without an
excess of stroke/SE compared with non-Asian races. Conflicting observations were previously
reported on this issue with the risks of death, stroke/SE, and bleeding found to be identical or
higher in Asians compared to non-Asians [27, 28]. In this report, these observations may be
due to confounding factors despite adjustment, as these patients were at lower risk than non-
Asian patients, as shown by their younger median age, lower rate of comorbidities, particularly
CKD, and lower CHA2DS2-VASc score. In addition, in some Asian countries, physicians rou-
tinely target a lower INR than in other regions, resulting in a significantly lower risk of bleed-
ing compared with non-Asian patients, yet with no excess risk of stroke/SE [29, 30].
Overall, two messages arise from this report. Firstly, several variables are linked to the risk
of one or more outcome measures. So far, the therapeutic approach recommended for the
management of AF emphasises rhythm and/or rate control and anticoagulation administered
in at-risk patients without contraindication. The decision for treatment is based on clinical
judgment and assessment of the risks of stroke/SE and bleeding using clinical risk scores, most
commonly CHA2DS2-VASc and HAS-BLED. Biomarker-based scores like the recently
described ABC score [31] cannot be used in a non-interventional registry, as blood sampling is
an intervention. In addition, this approach does not consider the most important risk for
patients with AF, namely the risk of death. Therefore, the tools used to assess risks need to be
revisited as many variables shown to have an impact on outcome are not included in the com-
monly used risk scores, and because the risk of death is not considered. For that reason, a new
scoring system addressing the risks of all three major outcome measures at once, namely
death, stroke/SE and bleeding, derived from a larger cohort may prove useful for clinicians.
Such a tool is under development using a larger GARFIELD-AF population as derivation
cohort and will be tested on an external validation cohort.
Secondly, this study shows that the comorbidities that strongly affect outcomes are under-
treated in at least one-third of patients with newly diagnosed AF. All comorbidities shown to
have an impact on outcomes should be addressed. In this regard, aggressive management of
CHF, CKD, and VascD and their risk factors, as well as smoking and drinking cessation,
should be strongly advocated. Strikingly, patients with comorbidities associated with the risk
of two or all three outcome measures, namely CHF, VascD, and CKD, are undertreated if we
consider the rates of prescription of guideline-recommended therapies. In patients with CHF,
depending on the New York Heart Association (NYHA) class, up to four drugs may be needed
[5]. Our data show that irrespective of the NYHA class, at least half of the patients were re-
ceiving a maximum of two drugs. In patients with VascD who should receive long term four
pharmacological classes, more than half of them were receiving a maximum of two [32].
Undertreatment has commonly been reported in various settings [33–37]. The situation for
CKD is more difficult to analyse, as the prescription of ACE/ARB is not unanimously recom-
mended and implemented, and is mostly driven by comorbidities [38, 39]. On the other hand,
implementation of guideline-recommended therapies was shown to improve outcomes, par-
ticularly in CHF and ACS [40–44]. Whether aggressive management of comorbidities in new-
onset AF has a favourable impact on outcomes is not yet known. Only controlled randomised
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trials comparing strict and lenient management strategies, and to some extent real-life pro-
spective registries such as GARFIELD-AF may help to answer this question.
Study limitations
We focused on three variables only when assessing the prescription rates of guideline-recom-
mended therapies. We cannot assume that our observations are valid for other variables. We
did not differentiate between CHF with preserved or reduced ejection fraction. In addition,
the collection of data on drug prescriptions in patients with CHF, VascD, and CKD may be
suboptimal since GARFIELD-AF is a study on patients with AF, and not specifically on these
entities.
Conclusions
Death is the most frequent adverse event in newly diagnosed AF, occurring at threefold the
rate of stroke/SE and fivefold the rate of major bleeding. Many modifiable variables have an
influence on the risk of one or more major outcome measures, particularly CHF, VascD, and
CKD, whose management seems suboptimal as regards the prescription of guideline-recom-
mended drugs in routine practice. Based upon these observations, we advocate for compre-
hensive management of newly diagnosed AF, particularly the implementation of guideline-
recommended therapies in CHF, VascD, and CKD, in addition to anticoagulation. Registries
like GARFIELD-AF may help to elucidate the causes of under treatment and to assess the
impact on outcomes of aggressive management of the most influential comorbidities.
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